Developer docs
API playgroundTry for free, no card

Search company profiles

Biosceptre

Full company profile

uuid0002uf9

Namestring
Biosceptre
Legal namestring
Biosceptre International Limited
Websiteurl
biosceptre.com
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer therapeutics, CAR-T therapy, monoclonal antibodies, peptide vaccines, immuno-oncology
Industry3 codes
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Therapeutic Development & Licensing
TypeLicensing Royalties
Description

As a clinical-stage biotech, Biosceptre is pre-revenue. The company develops novel cancer therapeutics targeting nfP2X7 across multiple modalities (antibodies, vaccines, CAR-T). Future revenue would likely come from licensing agreements with pharmaceutical partners, co-development deals, and eventual product commercialization.

biosceptre.com
2Research Grants & Government Funding
TypeProfessional Services
Description

Biosceptre has received multiple government-backed grants including UK Innovate UK SMART Award (£100,000), Technology Strategy Board Award (£150,000), and NHMRC Development Grant support. These non-dilutive funding sources support preclinical and clinical development programs.

biosceptre.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1BRiDGECAR™
Description

A universal CAR T system combining nfP2X7-targeted universal CAR T with multiple targeted antibodies for potential treatment of most forms of cancer.

biosceptre.com
+1 more record
Core offering1 text field

Biosceptre is a clinical-stage biotechnology company developing novel cancer therapeutics that target the non-functional P2X7 (nfP2X7) receptor, a cancer-specific antigen expressed across many cancer types but absent from healthy tissue. Its pipeline spans multiple modalities, including systemic monoclonal antibodies (BIL-03s), peptide vaccines (BIL06v), topical antibody therapy (BIL010t) for basal cell carcinoma, and the BRiDGECAR™ modular CAR-T platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 65% of BCC patients showed reduction in lesion area with BIL010t topical treatment
+3 more records
Product overview1 text field

Biosceptre is a biotechnology company developing a platform of cancer therapeutics targeting nfP2X7 (non-functional P2X7). The core technology centers on the BRiDGECAR™ System, a multiple-targeted universal CAR T platform that combines nfP2X7-targeted universal CAR T with multiple targeted antibodies. The product portfolio includes three clinical-stage candidates: BIL-03s (systemic human domain antibody for solid tumors), BIL06v (therapeutic peptide vaccine for solid tumors), and BIL010t (topical antibody treatment for Basal Cell Carcinoma). The company also offers the BridgeCAR™ Platform as an Adaptor CAR-T platform with a CD33-targeted AML module positioned for first-in-human evaluation. All products in the pipeline target the proprietary nfP2X7 receptor, a tumor-specific target absent from healthy tissue.

Product and service1 record
1BRiDGECAR™ System
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

Biosceptre's ongoing collaboration with Garvan on antibody development and optimisation has yielded promising monoclonal antibodies. Garvan's innovative protein design work uses x-ray crystallography, phage display and mutagenesis to humanize anti-peptide antibodies and modulate affinity. The work is supported by an NHMRC Development Grant.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-12-15
Description

Biosceptre partnered with UTS to establish a new analytical laboratory within the university's Biologics Innovation Facility (BIF). BIF is the only facility of its kind in an Australian University and the NSW node of the National Biologics Facility. The partnership provides translational support in antibody characterisation and development for Biosceptre's therapeutic programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-10-02
Description

Biosceptre acquired exclusive rights to Carina Biotech's nfP2X7-targeted CAR-T cells and associated intellectual property. Carina received upfront cash payment and equity in Biosceptre. The companies collaborate to further develop the nfP2X7 CAR-T program towards clinical trials. This represents Carina's first commercial agreement involving their proprietary CAR-T technology.

Strategic tierMinorTypeOthersAnnounced on2017-06-13
Description

Biosceptre joined the COST Group (European Cooperation in Science & Technology) project COST BMBS 1406, which created the Ion chan-Immune response network bringing together scientists and companies across 15 European countries to understand the function of ion channels in immune cells. P2X7 is central to the group's interest.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage cell therapy company developing SPEAR T-cell receptor therapies for solid tumors. Comparable to Biosceptre in modality (engineered T-cell therapy), stage (Phase I/II clinical), and target market (hard-to-treat solid tumors), with a similarly focused pipeline addressing limitations of conventional CAR-T.

TypeDirect peer
Description

Clinical-stage cell therapy company developing iPSC-derived NK and T-cell therapies for cancer. Comparable in modality (engineered cell therapy), stage (clinical), and oncology focus, with a platform approach to off-the-shelf cell-based cancer treatments.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing multi-tumor-associated antigen-specific T-cell therapies. Comparable in modality (T-cell therapy), stage (clinical), and focus on addressing solid tumors and hematologic malignancies with novel cell therapy approaches.

TypeDirect peer
Description

Australian clinical-stage biotech developing nfP2X7-targeted CAR-T cells and related oncology cell therapies. Biosceptre acquired exclusive rights to Carina's CAR-T technology in 2020, making them a direct technology peer and former collaborator working on the same target.

TypeDirect peer
Description

Clinical-stage gene editing company developing allogeneic CAR-T cell therapies (UCART). Direct peer in CAR-T modality, gene-edited cell therapy technology, and clinical-stage oncology focus, with comparable pipeline scope and platform approach.

TypeDirect peer
Description

Clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for cancer. Directly comparable in CAR-T modality and oncology focus, with a pipeline targeting hematologic malignancies and solid tumors using off-the-shelf cell therapy approaches.

TypeBroad incumbent
Description

Large biopharmaceutical company with Kite Pharma division developing and commercializing approved CAR-T therapies (Yescarta, Tecartus). Overlaps with Biosceptre in CAR-T modality and oncology focus, but operates at massive scale with multiple approved products and global commercial infrastructure.

TypeDirect peer
Description

Clinical-stage gene editing company developing CRISPR/Cas9-based gene-edited cell therapies (CASGEVY) for oncology and other indications. Comparable in gene-modified cell therapy modality, clinical-stage pipeline, and oncology focus with off-the-shelf CAR-T programs.

TypeDirect peer
Description

Clinical-stage gene editing company developing allogeneic CAR-T cell therapies using its ARCUS genome editing platform. Comparable in modality (CAR-T cell therapy), stage (clinical), and oncology focus with both hematologic and solid tumor programs.

TypeRegional player
Description

Australian clinical-stage immuno-oncology company developing cancer vaccines and B-cell immunotherapies (similar size, Australian operations, comparable development stage). Shares Biosceptre's Australian clinical trial site footprint and oncology vaccine modality overlap with the BIL06v peptide vaccine program.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biosceptre

Oncology Therapeuticsbiosceptre.com

Biosceptre firmographics

Firmographics
Name
Biosceptre
Legal name
Biosceptre International Limited
Website
https://biosceptre.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Biosceptre industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Cancer therapeutics
  • CAR-T therapy
  • Monoclonal antibodies
  • Peptide vaccines
  • Immuno-oncology

Where Biosceptre is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Biosceptre business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Therapeutic Development & Licensing: As a clinical-stage biotech, Biosceptre is pre-revenue. The company develops novel cancer therapeutics targeting nfP2X7 across multiple modalities (antibodies, vaccines, CAR-T). Future revenue would likely come from licensing agreements with pharmaceutical partners, co-development deals, and eventual product commercialization.
  2. Research Grants & Government Funding: Biosceptre has received multiple government-backed grants including UK Innovate UK SMART Award (£100,000), Technology Strategy Board Award (£150,000), and NHMRC Development Grant support. These non-dilutive funding sources support preclinical and clinical development programs.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Biosceptre product offering

Product offering

Core offering

Biosceptre is a clinical-stage biotechnology company developing novel cancer therapeutics that target the non-functional P2X7 (nfP2X7) receptor, a cancer-specific antigen expressed across many cancer types but absent from healthy tissue. Its pipeline spans multiple modalities, including systemic monoclonal antibodies (BIL-03s), peptide vaccines (BIL06v), topical antibody therapy (BIL010t) for basal cell carcinoma, and the BRiDGECAR™ modular CAR-T platform.

Product overview

Biosceptre is a biotechnology company developing a platform of cancer therapeutics targeting nfP2X7 (non-functional P2X7). The core technology centers on the BRiDGECAR™ System, a multiple-targeted universal CAR T platform that combines nfP2X7-targeted universal CAR T with multiple targeted antibodies. The product portfolio includes three clinical-stage candidates: BIL-03s (systemic human domain antibody for solid tumors), BIL06v (therapeutic peptide vaccine for solid tumors), and BIL010t (topical antibody treatment for Basal Cell Carcinoma). The company also offers the BridgeCAR™ Platform as an Adaptor CAR-T platform with a CD33-targeted AML module positioned for first-in-human evaluation. All products in the pipeline target the proprietary nfP2X7 receptor, a tumor-specific target absent from healthy tissue.

Differentiator

Problem solved

Functional benefit

Brands

  • BRiDGECAR™: A universal CAR T system combining nfP2X7-targeted universal CAR T with multiple targeted antibodies for potential treatment of most forms of cancer.
  • BridgeCAR™

Products and services

  • BRiDGECAR™ System

Quantifiable outcome

  • 65% of BCC patients showed reduction in lesion area with BIL010t topical treatment
  • +3 more outcomes

Companies that use Biosceptre

Customer profile

Segments3 records

Ideal customer profiles3 records

Biosceptre technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Biosceptre partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major, core and minor.

  • Garvan Institute of Medical ResearchmajorStrategic or Co-development Partner · 1 February 2025Biosceptre's ongoing collaboration with Garvan on antibody development and optimisation has yielded promising monoclonal antibodies. Garvan's innovative protein design work uses x-ray crystallography, phage display and mutagenesis to humanize anti-peptide antibodies and modulate affinity. The work is supported by an NHMRC Development Grant.
  • University of Technology Sydney (UTS)majorStrategic or Co-development Partner · 15 December 2020Biosceptre partnered with UTS to establish a new analytical laboratory within the university's Biologics Innovation Facility (BIF). BIF is the only facility of its kind in an Australian University and the NSW node of the National Biologics Facility. The partnership provides translational support in antibody characterisation and development for Biosceptre's therapeutic programs.
  • Carina BiotechcoreStrategic or Co-development Partner · 2 October 2020Biosceptre acquired exclusive rights to Carina Biotech's nfP2X7-targeted CAR-T cells and associated intellectual property. Carina received upfront cash payment and equity in Biosceptre. The companies collaborate to further develop the nfP2X7 CAR-T program towards clinical trials. This represents Carina's first commercial agreement involving their proprietary CAR-T technology.
  • COST Group BMBS 1406minorOthers · 13 June 2017Biosceptre joined the COST Group (European Cooperation in Science & Technology) project COST BMBS 1406, which created the Ion chan-Immune response network bringing together scientists and companies across 15 European countries to understand the function of ion channels in immune cells. P2X7 is central to the group's interest.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Biosceptre competitors and assessment

Company assessment

Direct peers

  • Adaptimmune: Clinical-stage cell therapy company developing SPEAR T-cell receptor therapies for solid tumors. Comparable to Biosceptre in modality (engineered T-cell therapy), stage (Phase I/II clinical), and target market (hard-to-treat solid tumors), with a similarly focused pipeline addressing limitations of conventional CAR-T.
  • Fate Therapeutics: Clinical-stage cell therapy company developing iPSC-derived NK and T-cell therapies for cancer. Comparable in modality (engineered cell therapy), stage (clinical), and oncology focus, with a platform approach to off-the-shelf cell-based cancer treatments.
  • Marker Therapeutics: Clinical-stage immuno-oncology company developing multi-tumor-associated antigen-specific T-cell therapies. Comparable in modality (T-cell therapy), stage (clinical), and focus on addressing solid tumors and hematologic malignancies with novel cell therapy approaches.
  • Carina Biotech: Australian clinical-stage biotech developing nfP2X7-targeted CAR-T cells and related oncology cell therapies. Biosceptre acquired exclusive rights to Carina's CAR-T technology in 2020, making them a direct technology peer and former collaborator working on the same target.
  • Cellectis: Clinical-stage gene editing company developing allogeneic CAR-T cell therapies (UCART). Direct peer in CAR-T modality, gene-edited cell therapy technology, and clinical-stage oncology focus, with comparable pipeline scope and platform approach.
  • Allogene Therapeutics: Clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for cancer. Directly comparable in CAR-T modality and oncology focus, with a pipeline targeting hematologic malignancies and solid tumors using off-the-shelf cell therapy approaches.
  • Crispr Therapeutics: Clinical-stage gene editing company developing CRISPR/Cas9-based gene-edited cell therapies (CASGEVY) for oncology and other indications. Comparable in gene-modified cell therapy modality, clinical-stage pipeline, and oncology focus with off-the-shelf CAR-T programs.
  • Precision Biosciences: Clinical-stage gene editing company developing allogeneic CAR-T cell therapies using its ARCUS genome editing platform. Comparable in modality (CAR-T cell therapy), stage (clinical), and oncology focus with both hematologic and solid tumor programs.

Broad incumbents

  • Gilead Sciences (Kite Pharma): Large biopharmaceutical company with Kite Pharma division developing and commercializing approved CAR-T therapies (Yescarta, Tecartus). Overlaps with Biosceptre in CAR-T modality and oncology focus, but operates at massive scale with multiple approved products and global commercial infrastructure.

Regional players

  • Imugene: Australian clinical-stage immuno-oncology company developing cancer vaccines and B-cell immunotherapies (similar size, Australian operations, comparable development stage). Shares Biosceptre's Australian clinical trial site footprint and oncology vaccine modality overlap with the BIL06v peptide vaccine program.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Biosceptre social profiles

Digital presence

Biosceptre financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biosceptre leadership team

Management profile

Number of profiles

Profiles11 records

Biosceptre subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Biosceptre funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biosceptre M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biosceptre

What does Biosceptre do?

Biosceptre is a clinical-stage biotechnology company developing novel cancer therapeutics that target the non-functional P2X7 (nfP2X7) receptor, a cancer-specific antigen expressed across many cancer types but absent from healthy tissue. Its pipeline spans multiple modalities, including systemic monoclonal antibodies (BIL-03s), peptide vaccines (BIL06v), topical antibody therapy (BIL010t) for basal cell carcinoma, and the BRiDGECAR™ modular CAR-T platform.

Is Biosceptre a public or private company?

Biosceptre is a private company. It is classified as venture growth investor backed and is currently operating.

When was Biosceptre founded?

Biosceptre was founded in 2014. It employs 11 to 50 people.

Where is Biosceptre based?

Biosceptre is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Biosceptre make money?

Two revenue lines are on record. Therapeutic Development & Licensing is the primary driver. The others are research Grants & Government Funding.

Who are Biosceptre's main competitors?

Direct peers on record are Adaptimmune, Fate Therapeutics, Marker Therapeutics, Carina Biotech, Cellectis, Allogene Therapeutics, Crispr Therapeutics and Precision Biosciences. Gilead Sciences (Kite Pharma) is listed as a broad incumbent. Imugene is listed as a regional player.

Does Biosceptre have an API?

No public API is recorded for Biosceptre.

What industry is Biosceptre in?

Biosceptre's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireInitiation of Biosceptre's Phase 1 Clinical Trial for First-in-Class Oncology Vaccine BIL06vBiosceptre has initiated its Phase I clinical trial for BIL06v, a first-in-class oncology peptide vaccine, with the first patient treated in Sydney on August 16, 2018. The trial focuses on prostate and lung cancer patients refractory to standard care and aims to recruit a full cohort of 20-30 participants within 12 months. Biosceptre is evaluating the safety, immunogenicity, and efficacy of targeting the nfP2X7 receptor to prevent cancer cell death.FinSMEsBiosceptre Receives Over £8M in Series A Funding - FinSMEsBiosceptre, a UK biotech, raised over £8M in Series A funding, with the round closing on 21 December 2017. The company will use the funds to progress its first systemic products targeting nfP2X7 in oncology, following a completed phase I trial.PR NewswirePharmaVentures Capital Limited Advises Biosceptre International Limited, a Clinical Stage Oncology Company, on its Series A Private Placement by Tuspark S&TPharmaVentures Capital Limited acted as adviser to Biosceptre International Limited on a Series A private placement completed by Tuspark Science & Technology Service Group, a Chinese conglomerate, through its investment vehicle Bluesky Partnership II L.P. The deal, Tuspark's first major overseas investment into biotech, will fund the advancement of Biosceptre's three oncology clinical assets — BIL010t, BIL06v, and BIL03s — targeting the nfP2X7 cancer pathway. Clinical trials are planned across Australia, the UK and the EU, with Biosceptre headquartered in Cambridge, UK.PR NewswireBiosceptre welcomes Tuspark S & T into its Series A fund raising roundBiosceptre, a Cambridge, UK-based biotechnology company, has received over £8 million in Series A funding, with the majority led by Tuspark Science and Technology Service Group, the venture arm of Tsinghua University in Beijing. The funding will support progression of clinical trials for cancer treatments targeting nfP2X7, including a Phase I trial of the peptide vaccine BIL06v scheduled to begin at three sites in Sydney, Australia in 2018. The company anticipates announcing clinical milestones over the next 18 months, which could facilitate an IPO or trade sale as early as 2019.PR NewswireSir Gregory Winter joins Biosceptre BoardBiosceptre announced that Sir Gregory Winter has joined its board of directors as a non-executive director, expanding his previous role as chair of the Scientific Advisory Board. The company plans to initiate three additional clinical trials in 2016 for its nfP2X7-targeting therapeutic candidates following a successful phase I trial.